Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: ISRCTN44297014. We help you review the study, but cannot decide medical eligibility.
Not recruitingISRCTN44297014
A phase III active comparator-controlled study to study the safety and efficacy of lurasidone in subjects with schizophrenia (PEARL 3 extension study)
This study is not recruiting in the United States, in Colombia, in Germany, .... It focuses on schizophrenia.
Schizophrenia, Mental healthOtherFrom 18 Years to 75 Years
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Compensation and expense reimbursement have not been verified for this summary.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Dainippon Sumitomo Pharma America Inc. (USA)
- Sponsor type
- Pharmaceutical company
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- United States, Colombia, Germany, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- ISRCTN44297014
- Official title
- A phase III randomised, double-blind, active comparator-controlled clinical trial to study the safety and efficacy of lurasidone in subjects with schizophrenia (PEARL 3 extension study)
Recruitment & locations
Not recruitingColombia · Germany · India
5 more locations
- Philippines
- Romania
- Russia
- Ukraine
- United States
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Dainippon Sumitomo Pharma America Inc. (USA), a pharmaceutical company.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Not recruitingISRCTN33909010
Placebo- and active comparator-controlled, study to study the safety and efficacy of two doses of lurasidone HCL in acutely psychotic people with schizophrenia
This study is not recruiting in the United Kingdom, in Bulgaria, in Colombia, .... It focuses on schizophrenia.
Not recruitingISRCTN16838597
A phase three study to study the safety and efficacy of three doses of lurasidone hydrochloride (HCl) in acutely psychotic people with schizophrenia
This study is not recruiting in the United States, in France, in the United Kingdom, .... It focuses on schizophrenia.
Not recruitingISRCTN56877013
Effectiveness of usual, facility based care compared to an additional collaborative community care package in schizophrenia
This study is not recruiting in the United Kingdom and in India. It is testing usual, facility based care compared to an additional collaborative community care package for schizophrenia.